



Regulus Therapeutics Inc.
Investor Relations Department
10614 Science Center Dr
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

Last Trade:	1.11
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.86 - 4.25
Volume	13,300

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*SM biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 25, 2017 [Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares](#)
- Jul 25, 2017 [Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017](#)
- Jul 19, 2017 [Regulus Announces Pricing of Public Offering of Common Stock](#)
- Jul 19, 2017 [Regulus Announces Commencement of Public Offering of Common Stock](#)
- Jun 13, 2017 [Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer](#)

Upcoming Events [\[View all \]](#)

- Aug 1, 2017 5:00 PM ET [Regulus Therapeutics Inc. Second Quarter 2017 Conference Call](#)
- [Financials \[\\[View all \\]\]\(#\)](#)
 - [First Quarter Financial Results](#)
- Mar 3, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 2, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 3, 2016 [Quarterly Report \(10-Q\)](#)